Engineered HMGB1 construct with tandem Box B domains promotes tissue regeneration without potential for deleterious inflammation or thrombosis
Alvaro Viñals Guitart, Carl LeeiD, Ana Isabel Espirito Santo, Jia-Ling RuaniD, Shih-Hsuan Mao, Lynn William, Christina RedfieldiD, Oleg FedoroviD, N. Burgess-BrowniD, Wyatt W. YueiD, Jagdeep NanchahaliD
Abstract
Fully reduced High Mobility Group Box 1 (HMGB1) binds CXCL12 and signals via CXCR4 when released into the extracellular space. It acts as a chemokine and transitions stem cells from quiescent G to a primed GAlert state. Cells in GAlert rapidly enter G1 in response to activating factors released by tissue injury to promote tissue repair. However, oxidative conversion of FR-HMGB1 into the disulfide form activates proinflammatory pathways via TLR-2, TLR-4 and RAGE. Peptide mapping and NMR spectroscopy identified a conserved CXCL12-binding motif within each Box and adjacent flanking regions. We decoupled the regenerative and inflammatory functions using an engineered construct (dBB12L), comprising tandem Box B domains with a flexible linker. dBB12L exhibited CXCL12 binding and accelerated repair equivalent to FR-HMGB1. Importantly, dBB12L lacked detectable RAGE binding and did not signal via TLR-2 and TLR-4, establishing it as a potential therapeutic to promote tissue repair without deleterious inflammation.
02 /Specification & Classification
Click any tag to browse matching papers- Citations
- 1
- FWCI
- 4.67
- Field percentile
- top 5%
- Research Focus
- Approach
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Systematic development of peptide inhibitors targeting the CXCL12/HMGB1 interaction
J. Sgrignani, V. Cecchinato, … A. Cavalli·bioRxiv·Dec 18, 2019
- Diflunisal targets the HMGB1/CXCL12 heterocomplex and blocks immune cell recruitment
F. De Leo, G. Quilici, … G. Musco·bioRxiv·Mar 1, 2019
- Oxidation state dependent conformational changes of HMGB1 regulates the formation of the CXCL12/HMGB1 heterocomplex
E. M. A. Fassi, J. Sgrignani, … A. Cavalli·bioRxiv·May 28, 2019
- The acidic intrinsically disordered region of the inflammatory mediator HMGB1 mediates fuzzy interactions with chemokine CXCL12
M. V. Mantonico, F. De Leo, … G. Musco·bioRxiv·Jun 6, 2023
- A Potent Nonapeptide Inhibitor for the CXCL12/HMGB1 heterocomplex: A Computational and Experimental Approach
Enrico Mario Alessandro Fassi, Edisa Pirani, … Giovanni Grazioso·Computational and Structural Biotechnology JournalPeer-reviewed·Jan 1, 2025
- Discovery of 5,5'-methylenedi-2,3-cresotic acid as a potent inhibitor of the HMGB1/CXCL12 heterocomplex using Virtual Screening and NMR validation
F. De Leo, Q. Giacomo, … G. Musco·bioRxiv·Aug 25, 2020